{"id":153460,"date":"2026-08-27T17:39:26","date_gmt":"2026-08-27T17:39:26","guid":{"rendered":"https:\/\/www.europesays.com\/ai\/153460\/"},"modified":"2026-08-27T17:39:26","modified_gmt":"2026-08-27T17:39:26","slug":"global-cognitive-computing-and-artificial-intelligence-systems-market-in-healthcare-to-reach-significant-scale-driven-by-rising-chronic-disease-burden-and-healthcare-digitalization","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ai\/153460\/","title":{"rendered":"Global Cognitive Computing and Artificial Intelligence Systems Market in Healthcare to Reach Significant Scale, Driven by Rising Chronic Disease Burden and Healthcare Digitalization"},"content":{"rendered":"

\"BCC<\/a> BCC Research LLC <\/p>\n

“Rising chronic disease, clinician shortages and healthcare digitalization are driving AI adoption across diagnostics, patient monitoring and drug discovery, while the deep learning segment is projected to grow at approximately 36.1% as hospitals scale image analysis and clinical decision-support platforms.” <\/p>\n

Boston, Aug. 27, 2026 (GLOBE NEWSWIRE)<\/a> — The global cognitive computing and artificial intelligence systems market in healthcare is undergoing rapid structural expansion, powered by accelerating demand for AI-enabled diagnostics, clinical decision support, and scalable patient monitoring solutions. BCC Research’s newly published report, Global Cognitive Computing and Artificial Intelligence Systems Market in Healthcare<\/a>, provides comprehensive market sizing, segmentation analysis, and competitive intelligence across the forecast period. <\/p>\n

Key Findings <\/p>\n

\u2022 Market expansion is driven by the compounding pressure of chronic disease prevalence and digitalization. Rising incidences of diabetes, cancer, and cardiovascular conditions are generating sustained demand for AI-powered clinical decision support and diagnostic analytics, while deep learning \u2014 leveraging multilayer neural networks for image-based disease detection and precision diagnostics \u2014 is forecast to grow at a CAGR of approximately 36.1% over the forecast period, underscoring the pace of technological adoption.
\u2022 North America holds the largest regional share at 27.4%, with Europe tied at 27.4% in 2024. North America’s position reflects mature healthcare IT infrastructure, strong venture and institutional investment in health AI, and broad enterprise adoption by integrated health systems. Europe’s near-equal share is supported by government-mandated digital health programs including the NHS digital transformation in the U.K. and Germany’s Digital Healthcare Act (DVG).
\u2022 Imaging workload growth and a global shortage of skilled radiologists and pathologists are accelerating AI platform adoption. Hospitals and diagnostic centers facing unsustainable read volumes are turning to AI-enabled diagnostic platforms to improve throughput, reduce error rates, and extend specialist capacity \u2014 creating durable, recurring demand across both developed and emerging markets.
\u2022 Pharmaceutical and biotechnology companies are materially increasing AI investment to compress drug discovery timelines. AI-driven analytics platforms are being deployed to improve compound screening, optimize clinical trial design, and reduce time-to-market \u2014 drawing significant R&D capital into the broader cognitive computing ecosystem and expanding the total addressable market beyond clinical settings.
\u2022 A cluster of emerging technologies is reshaping the competitive frontier. Generative AI platforms such as Tempus One and AWS HealthScribe are entering radiology reporting and EHR integration workflows. Large language models including Med-PaLM 2 and MedLM are advancing clinical reasoning capabilities. GPU-accelerated genomics tools such as NVIDIA Parabricks, edge AI infrastructure for point-of-care inference, and AI-driven digital pathology platforms including PathAI AISight Dx for precision oncology are collectively expanding the solution landscape.
\u2022 The competitive landscape is highly fragmented across technology hyperscalers, medical device incumbents, and pure-play AI specialists. Key participants include Alphabet Inc. (Google Inc.), Microsoft, IBM Corp., NVIDIA Corp., Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare, Amazon Web Services Inc., Oracle, Intel Corp., Medtronic, Tempus, Viz.ai Inc., PathAI Inc., and Datavant. <\/p>\n

Market Drivers <\/p>\n

The structural case for AI adoption in healthcare rests on converging demographic and systemic pressures. Expanding geriatric populations across North America, Europe, and Asia-Pacific are straining care coordination capacity, elevating demand for AI-driven patient monitoring solutions that can operate at scale without proportional increases in clinical headcount. Simultaneously, public sector commitment to digital health infrastructure \u2014 from Brazil’s National Digital Health Strategy to broader NHS modernization \u2014 is establishing the policy and connectivity foundations necessary for enterprise-scale AI deployment.
Cloud-based hospital information systems and radiology informatics platforms, including Philips HealthSuite Imaging on AWS, are lowering deployment barriers by enabling scalable, interoperable access to cognitive computing tools. Significant government and private-sector investment in cloud and AI infrastructure is reinforcing this environment, creating tailwinds for both incumbent platform providers and emerging AI-native vendors competing for institutional contracts. <\/p>\n

Investment Considerations <\/p>\n

Investors evaluating this market should weigh the deep learning segment’s projected ~36.1% CAGR as a signal of where capital is concentrating and where differentiated returns are most likely to emerge. Hyperscalers \u2014 Microsoft, AWS, and Alphabet \u2014 benefit from existing enterprise relationships and cloud infrastructure advantages, while specialized players such as NVIDIA (GPU-accelerated clinical computing), PathAI (digital pathology), and Viz.ai (AI-powered clinical workflows) offer more targeted exposure to high-growth verticals. Key risks include regulatory uncertainty around AI medical device classification, the persistent “black box” transparency problem limiting clinician trust and complicating reimbursement pathways, HIPAA and data privacy compliance costs, and geopolitical headwinds in China affecting global players including Koninklijke Philips N.V. Adoption of explainable AI frameworks and robust EHR interoperability will be meaningful differentiators in procurement decisions going forward. <\/p>\n

About the Report <\/p>\n

Global Cognitive Computing and Artificial Intelligence Systems Market in Healthcare<\/a> provides full market sizing, regional and segment-level forecasting, emerging technology analysis, and competitive intelligence across the forecast period. <\/p>\n

About BCC Research <\/p>\n

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process.
For media inquiries, email press@bccresearch.com<\/a> or visit our media page<\/a> for access to our market research library. <\/p>\n

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC<\/a> as the source and publisher. <\/p>\n","protected":false},"excerpt":{"rendered":"BCC Research LLC “Rising chronic disease, clinician shortages and healthcare digitalization are driving AI adoption across diagnostics, patient…\n","protected":false},"author":2,"featured_media":153461,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[24,25,17539,7598,23568,2609,7287,545,6936,74778,49,36780,50244,74777,74775,2785,74776,6600],"class_list":["post-153460","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ai","tag-ai","tag-artificial-intelligence","tag-clinical-decision-support","tag-cognitive-computing","tag-competitive-intelligence","tag-digital-health","tag-digital-pathology","tag-digital-transformation","tag-ge-healthcare","tag-global-shortage","tag-healthcare","tag-institutional-investment","tag-market-expansion","tag-market-sizing","tag-monitoring-solutions","tag-north-america","tag-precision-diagnostics","tag-total-addressable-market"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/153460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=153460"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/153460\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/153461"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=153460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=153460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=153460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}